Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes

Yingqiu Xie, Sanzhar Naizabekov, Zhanlin Chen, Tursonjan Tokay

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

An increasing amount of evidence has shown that tumor suppressors can become oncogenes, or vice versa, but the mechanism behind this is unclear. Recent findings have suggested that phosphatase and tensin homolog (PTEN) is one of the powerful switches for the conversion between tumor suppressors and oncogenes. PTEN regulates a number of cellular processes, including cell death and proliferation, through the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Furthermore, a number of studies have suggested that PTEN deletions may alter various functions of certain tumor suppressor and oncogenic proteins. The aim of the present review was to analyze specific cases driven by PTEN loss/AKT activation, including aberrant signaling pathways and novel drug targets for clinical application in personalized medicine. The findings illustrate how PTEN loss and/or AKT activation switches MDM2-dependent p53 downregulation, and induces conversion between oncogene and tumor suppressor in enhancer of zeste homolog 2, BTB domain-containing 7A, alternative reading frame 2, p27 and breast cancer 1, early onset, through multiple mechanisms. This review highlights the genetic basis of complex drug targets and provides insights into the rationale of precision cancer therapy.

Original languageEnglish
Pages (from-to)375-378
Number of pages4
JournalOncology Letters
Volume12
Issue number1
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Oncogenes
Phosphoric Monoester Hydrolases
Neoplasms
Tumor Suppressor Proteins
Reading Frames
Proto-Oncogene Proteins c-akt
Precision Medicine
1-Phosphatidylinositol 4-Kinase
Sirolimus
Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Cell Death
Down-Regulation
Cell Proliferation
Tensins
Breast Neoplasms
Therapeutics

Keywords

  • Molecular switch
  • Oncogene
  • PTEN
  • Tumor suppressor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Power of PTEN/AKT : Molecular switch between tumor suppressors and oncogenes. / Xie, Yingqiu; Naizabekov, Sanzhar; Chen, Zhanlin; Tokay, Tursonjan.

In: Oncology Letters, Vol. 12, No. 1, 01.07.2016, p. 375-378.

Research output: Contribution to journalReview article

Xie, Yingqiu ; Naizabekov, Sanzhar ; Chen, Zhanlin ; Tokay, Tursonjan. / Power of PTEN/AKT : Molecular switch between tumor suppressors and oncogenes. In: Oncology Letters. 2016 ; Vol. 12, No. 1. pp. 375-378.
@article{1dc0227f1d2248dfa9b48407b4f68d18,
title = "Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes",
abstract = "An increasing amount of evidence has shown that tumor suppressors can become oncogenes, or vice versa, but the mechanism behind this is unclear. Recent findings have suggested that phosphatase and tensin homolog (PTEN) is one of the powerful switches for the conversion between tumor suppressors and oncogenes. PTEN regulates a number of cellular processes, including cell death and proliferation, through the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Furthermore, a number of studies have suggested that PTEN deletions may alter various functions of certain tumor suppressor and oncogenic proteins. The aim of the present review was to analyze specific cases driven by PTEN loss/AKT activation, including aberrant signaling pathways and novel drug targets for clinical application in personalized medicine. The findings illustrate how PTEN loss and/or AKT activation switches MDM2-dependent p53 downregulation, and induces conversion between oncogene and tumor suppressor in enhancer of zeste homolog 2, BTB domain-containing 7A, alternative reading frame 2, p27 and breast cancer 1, early onset, through multiple mechanisms. This review highlights the genetic basis of complex drug targets and provides insights into the rationale of precision cancer therapy.",
keywords = "Molecular switch, Oncogene, PTEN, Tumor suppressor",
author = "Yingqiu Xie and Sanzhar Naizabekov and Zhanlin Chen and Tursonjan Tokay",
year = "2016",
month = "7",
day = "1",
doi = "10.3892/ol.2016.4636",
language = "English",
volume = "12",
pages = "375--378",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Power of PTEN/AKT

T2 - Molecular switch between tumor suppressors and oncogenes

AU - Xie, Yingqiu

AU - Naizabekov, Sanzhar

AU - Chen, Zhanlin

AU - Tokay, Tursonjan

PY - 2016/7/1

Y1 - 2016/7/1

N2 - An increasing amount of evidence has shown that tumor suppressors can become oncogenes, or vice versa, but the mechanism behind this is unclear. Recent findings have suggested that phosphatase and tensin homolog (PTEN) is one of the powerful switches for the conversion between tumor suppressors and oncogenes. PTEN regulates a number of cellular processes, including cell death and proliferation, through the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Furthermore, a number of studies have suggested that PTEN deletions may alter various functions of certain tumor suppressor and oncogenic proteins. The aim of the present review was to analyze specific cases driven by PTEN loss/AKT activation, including aberrant signaling pathways and novel drug targets for clinical application in personalized medicine. The findings illustrate how PTEN loss and/or AKT activation switches MDM2-dependent p53 downregulation, and induces conversion between oncogene and tumor suppressor in enhancer of zeste homolog 2, BTB domain-containing 7A, alternative reading frame 2, p27 and breast cancer 1, early onset, through multiple mechanisms. This review highlights the genetic basis of complex drug targets and provides insights into the rationale of precision cancer therapy.

AB - An increasing amount of evidence has shown that tumor suppressors can become oncogenes, or vice versa, but the mechanism behind this is unclear. Recent findings have suggested that phosphatase and tensin homolog (PTEN) is one of the powerful switches for the conversion between tumor suppressors and oncogenes. PTEN regulates a number of cellular processes, including cell death and proliferation, through the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Furthermore, a number of studies have suggested that PTEN deletions may alter various functions of certain tumor suppressor and oncogenic proteins. The aim of the present review was to analyze specific cases driven by PTEN loss/AKT activation, including aberrant signaling pathways and novel drug targets for clinical application in personalized medicine. The findings illustrate how PTEN loss and/or AKT activation switches MDM2-dependent p53 downregulation, and induces conversion between oncogene and tumor suppressor in enhancer of zeste homolog 2, BTB domain-containing 7A, alternative reading frame 2, p27 and breast cancer 1, early onset, through multiple mechanisms. This review highlights the genetic basis of complex drug targets and provides insights into the rationale of precision cancer therapy.

KW - Molecular switch

KW - Oncogene

KW - PTEN

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=84973443327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973443327&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4636

DO - 10.3892/ol.2016.4636

M3 - Review article

AN - SCOPUS:84973443327

VL - 12

SP - 375

EP - 378

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -